Olinvacimab Biosimilar – Anti-KDR, VEGFR2 mAb – Research Grade

Description of Olinvacimab Biosimilar - Anti-KDR, VEGFR2 mAb - Research Grade

Introduction

Olinvacimab Biosimilar, also known as Anti-KDR, VEGFR2 mAb – Research Grade, is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2 or KDR). It is a biosimilar version of the original drug, Olinvacimab, and is currently being studied for its potential therapeutic applications in various diseases. In this article, we will explore the structure, activity, and potential applications of Olinvacimab Biosimilar.

Structure of Olinvacimab Biosimilar

Olinvacimab Biosimilar is a monoclonal antibody, which means it is a type of protein that is designed to bind to a specific target in the body. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains are made up of constant and variable regions, while the light chains only have a variable region.

The variable regions of Olinvacimab Biosimilar are responsible for its specificity towards VEGFR2. This means that the antibody is designed to bind to a specific site on the VEGFR2 receptor, preventing the binding of its natural ligand, VEGF. This prevents the activation of the receptor and ultimately inhibits the growth of new blood vessels, which is the main function of VEGFR2.

Activity of Olinvacimab Biosimilar

As mentioned earlier, the main activity of Olinvacimab Biosimilar is to inhibit the growth of new blood vessels. This is achieved by binding to VEGFR2 and preventing the binding of VEGF, which is a key factor in the process of angiogenesis. Angiogenesis is the formation of new blood vessels, which is crucial for the growth and spread of tumors in cancer.

In addition to its anti-angiogenic activity, Olinvacimab Biosimilar also has anti-tumor effects. This is because VEGFR2 is not only involved in angiogenesis, but also in tumor cell proliferation, survival, and migration. By targeting VEGFR2, Olinvacimab Biosimilar can inhibit these processes and potentially slow down the growth and spread of tumors.

Applications of Olinvacimab Biosimilar

Olinvacimab Biosimilar is currently being studied for its potential therapeutic applications in various diseases, including cancer, diabetic retinopathy, and age-related macular degeneration (AMD). The main focus of research is on its potential as an anti- cancer drug, particularly in the treatment of solid tumors such as breast, lung, and colon cancers.

In preclinical studies, Olinvacimab Biosimilar has shown promising results in inhibiting tumor growth and improving survival rates in animal models. It has also been found to enhance the effects of chemotherapy and radiation therapy when used in combination. These findings suggest that Olinvacimab Biosimilar has the potential to be an effective treatment option for cancer patients.

In addition to cancer, Olinvacimab Biosimilar is also being investigated for its potential in treating ocular diseases such as diabetic retinopathy and AMD. These diseases are characterized by abnormal growth of blood vessels in the eye, which can lead to vision loss. By inhibiting VEGFR2, Olinvacimab Biosimilar may be able to prevent the growth of these abnormal blood vessels and improve the outcomes for patients with these conditions.

Conclusion

In summary, Olinvacimab Biosimilar is a monoclonal antibody that targets VEGFR2 and has anti-angiogenic and anti-tumor activities. It is currently being studied for its potential therapeutic applications in various diseases, with a focus on cancer. Its unique mechanism of action and promising preclinical results make it a promising candidate for the treatment of cancer and other diseases involving abnormal blood vessel growth. Further research and clinical trials are needed to fully understand the potential of Olinvacimab Biosimilar and its role in improving patient outcomes.

Olinvacimab Biosimilar - Anti-KDR, VEGFR2 mAb binds to Human VEGFR2 Recombinant Protein in indirect ELISA Assay

Immobilized Human VEGFR2 Recombinant Protein (cat. No.PX-P3059) at 0.5µg/mL (100µL/well) can bind to Olinvacimab Biosimilar - Anti-KDR, VEGFR2 mAb (cat. No.PX-TA1520) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450